FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

BioNTech Partial Hold on Lung Cancer Trial

FDA issues a partial clinical hold on a BioNTech and OncoC4, Phase 3 trial that is assessing gotistobart in non-small cell lung cancer.

latest-news-card-1
Federal Register

Guide on Post-Op Nausea Drug Development

Federal Register notice: FDA makes available a draft guidance entitled Postoperative Nausea and Vomiting: Developing Drugs for Prevention.

latest-news-card-1
Federal Register

Guide on Oncology Patient-Reported Outcomes

Federal Register notice: FDA makes available a final guidance entitled Core Patient-Reported Outcomes in Cancer Clinical Trials.

latest-news-card-1
Federal Register

Guide on Neonatal Neurodevelopmental Safety Studies

Federal Register notice: FDA makes available a final guidance entitled Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neon...

latest-news-card-1
Human Drugs

Guide on ANDA Drug Master File Reviews

FDA releases a guidance entitled Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA. `

latest-news-card-1
Human Drugs

Gilead Pulls Trodelvy Urothelial Cancer Indications

Gilead Sciences withdraws the accelerated approval for a Trodelvy (sacituzumab govitecan-hziy) indication for treating adult patients with locally adv...

latest-news-card-1
Human Drugs

Avadel Wins Expanded Label for Lumryz

FDA approves an Avadel Pharmaceuticals supplemental NDA for Lumryz (sodium oxybate) for treating cataplexy or excessive daytime sleepiness in patients...

latest-news-card-1
Medical Devices

Boston Scientific Recalls Obsidio Embolic Device

Boston Scientific recalls (Class 1) its Obsidio Conformable Embolic device to update the use instructions due to a concern about risks when using it a...

latest-news-card-1

Neurodevelopmental Safety Studies in Neonatal Products

FDA publishes a guidance outlining a framework for considering the types of long-term neurodevelopmental safety studies that could support a determina...

latest-news-card-1
Human Drugs

FDA Continues to Review Ocaliva sNDA

FDA says it is continuing to review the sNDA submitted by Intercept Pharmaceuticals for its Ocaliva following an advisory committee 10-1 vote not to r...